Supplemental Table 1 from Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma
Niki Gavrielatou(National and Kapodistrian University of Athens), David L. Rimm(Yale University), Sneha Burela(Yale University), Thazin Nwe Aung(Yale University), Periklis Foukas(National and Kapodistrian University of Athens), Barbara Burtness(Yale University), Μaria Anastasiou(National and Kapodistrian University of Athens), Aileen I. Fernandez(Yale University), Amanda Psyrri(National and Kapodistrian University of Athens), Myrto Moutafi(University General Hospital Attikon), Ioannis Vathiotis(Yale University), Saba Shafi(Ministry of Education of the People's Republic of China), Panagiota Economopoulou(National and Kapodistrian University of Athens)
Cited by 0
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma
|Nature|2005|1.5k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k